CA
NZ
UK
AU
IND
US
US Treasuries are facing downward pressure asMarket Participantsprepare for significant inflation data expected later in the week. The anticipation is evident, with yields reacting to shifting economic indicators, including rising oil prices that have elicited broader market concerns. As investors weigh potential inflationary impacts, …
USDA's new sterile fly facility in Texas is slated to open in spring 2027, enhancing pest management strategies essential for U.S. agriculture. This project aims to help control destructive pests, providing farmers with advanced tools to mitigate crop damage. With the growing need for …
Trump’s recent demand for Iran to pay compensation for lives lost and affected by its actions has significantly altered perceptions in the geopolitical environment. This assertion comes amid ongoing negotiations related to the Strait of Hormuz, a key corridor for global oil. The heightened …
President Trump’s plan for Gaza hinges on two key actions: the disarmament of Hamas and the withdrawal of Israeli forces. These strategic conditions aim to reshape the regional environment and ease tensions in the Israel-Palestine conflict.
Ashland Inc. has made its 19th officer or director change since August 2022, underscoring a period of heightened executive adjustments. The move is key, as it aims to enhance corporate governance transparency amid shifting industry dynamics.
Zura Bio Ltd posted a net loss of $26.3 million for the second quarter, with cash reserves at $205.1 million ensuring funding through 2028. The robust enrollment inClinical Trialspositions the company favorably for upcoming data readouts, crucial for investor confidence.Key HighlightsEnrollment in TibuSHIELD and …
Tenax Therapeutics (NASDAQ: TENX) saw its stock surge 6.9% to $1.47 in early trading after management highlighted data from the Phase III LEVEL trial of oral levosimendan in patients with heart failure with preserved ejection fraction (HFpEF). The announcement came amid a steep 87.6% …
Upstream Bio, Inc. reported an EPS of $-0.75 for the second quarter, exceeding the consensus estimate of $-0.78. The positive variance indicates clinical advancements that may bolster investor confidence as the company approaches key trial initiations.Key HighlightsQ2Research and Developmentexpenses fell to $36.1 million from …
Theriva Biologics, Inc. reported a net loss of $5.3 million for the quarter ended June 30, 2026, alongside cash and cash equivalents of $11.3 million. This is critical for investors assessing the company's financial flexibility as it advances its clinical programs.Key HighlightsNet loss narrowed …
Vireo Growth Inc. reported anEarnings Per Share(EPS) of $0.00 for the second quarter ending June 30, showing the company's ongoing strategic realignment amid aMergerplan with Planet 13 Holdings. This stagnation in earnings, alongside a volatile share performance, may concern investors looking for growth.Key HighlightsVireo …
Please wait processing your request...